These results supported the use of Lipo[MNP@m-SiO2] for targeted drug delivery in Her2/neu positive breast cancer cases; nevertheless, further work is recommended to evaluate its in vivo behavior and to monitor its therapeutic outcomes [68]. Here, ERBB2 is linked to breast carcinoma.